Table 2. Risk of tuberculosis (TB) recurrence in different subgroups.
| Characteristics | No. at risk | No. (%) with recurrence | p value* | |
|---|---|---|---|---|
| Age (years) | >49 | 131 | 6 (4.6%) | 0.410 |
| ≤49 | 377 | 12 (3.2%) | ||
| Sex | Women | 54 | 0 (0%) | 0.147 |
| Men | 454 | 18 (4.0%) | ||
| Timing of TB diagnosis | Pre-DOTS era | 299 | 16 (5.4%) | 0.014 |
| DOTS era | 209 | 2 (1.0%) | ||
| Comorbidity | Present | 60 | 1 (1.7%) | 0.429 |
| Absent | 448 | 17 (3.8%) | ||
| Low income | Yes | 14 | 0 (0%) | 0.472 |
| No | 494 | 18 (3.6%) | ||
| Anti-HIV Tx during anti-TB Tx | cART | 185 | 5 (2.7%) | 0.042 |
| Not cART | 122 | 1 (0.8%) | ||
| No | 201 | 12 (6.0%) | ||
| Duration of anti-TB treatment | <195 days | 85 | 5 (5.9%) | 0.056 |
| 195–270 days | 174 | 9 (5.2%) | ||
| >270 days | 249 | 4 (1.6%) | ||
| Total duration of isoniazid administration | <240 days | 302 | 15 (5.0%) | 0.030 |
| ≥240 days | 206 | 3 (1.5%) | ||
| Total duration of rifamycin administration | <240 days | 329 | 15 (4.6%) | 0.090 |
| ≥240 days | 179 | 3 (1.7%) | ||
| Total duration of ethambutol administration | <240 days | 310 | 14 (4.5%) | 0.109 |
| ≥240 days | 198 | 4 (2.0%) | ||
| Total duration of pyrazinamide administration | <60 days | 180 | 5 (2.8%) | 0.410 |
| ≥60 days | 328 | 13 (4.0%) | ||
| Consistency with standards # | >80% | 134 | 4 (3.0%) | 0.734 |
| ≤80% | 374 | 14 (3.7%) |
cART, combination antiretroviral therapy; DOTS, directly observed therapy, short course; HIV, human immunodeficiency virus; Tx, treatment.
*Timing of TB recurrence was compared using the log-rank test.
#receiving isoniazid, rifamycin, ethambutol, and pyrazinamide for >48 days in the first 2 months, and isoniazid and rifamycin for >144 days in the first 6 months of anti-TB treatment.